E-7090
As of the edition of 20 October 2026, E-7090 is a small molecule: marketed, first approved in 2024 (JP); acts on FGFR1, FGFR2 and FGFR3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Tasfygo
- First approved
- 24 September 2024 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Eisai
- Registered trials
- 7, 0 stopped early
- Disease areas
- Bones, joints and muscles; Cancer; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of E-7090.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 4 | 1 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eisai | Applicant and Lead sponsor of trials | 2014 to now |